| Bianca Marie Seivley, PA-C | |
|
500 W 144th Ave Ste 230, Westminster, CO 80023-9328 | |
| (303) 665-2603 | |
| Not Available |
| Full Name | Bianca Marie Seivley |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 5 Years |
| Location | 500 W 144th Ave Ste 230, Westminster, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518582352 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | PA.0005992 (Colorado) | Secondary |
| 363A00000X | Physician Assistant | PA.0005992 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Centura Health-avista Adventist Hospital | Louisville, CO | Hospital |
| Lutheran Medical Center | Wheat ridge, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthopedic Centers Of Colorado | 2365714540 | 298 |
News Archive
International telepathology consultations can significantly improve patient care, according to a new study by UPMC and KingMed Diagnostics researchers. Their review of more than 1,500 pathology cases submitted electronically to UPMC over three years found that consultation with UPMC pathologists resulted in significantly altered treatment plans for more than half of the cases in which a patient's primary diagnosis had been provided from referring hospitals in China.
GlaxoSmithKline and Genmab A/S announced today an amendment to the ofatumumab co-development and commercialisation agreement. Under the terms of the amendment, GSK will take responsibility for developing ofatumumab in autoimmune indications whilst continuing to jointly develop ofatumumab with Genmab in oncology indications.
Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).
Prof. Jiunn-Der Liao of Department of Materials Science and Engineering at National Cheng Kung University (NCKU), Tainan, Taiwan, has led Post Doctorate Chih-Chiang Weng and a research team to develop a pen-size plasma sterilization device which can sterilize instruments and wounds by relying on the process of plasma sterilization.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bianca Marie Seivley, PA-C 3 Superior Dr Ste 225, Superior, CO 80027-8661 Ph: (303) 665-2603 | Bianca Marie Seivley, PA-C 500 W 144th Ave Ste 230, Westminster, CO 80023-9328 Ph: (303) 665-2603 |
News Archive
International telepathology consultations can significantly improve patient care, according to a new study by UPMC and KingMed Diagnostics researchers. Their review of more than 1,500 pathology cases submitted electronically to UPMC over three years found that consultation with UPMC pathologists resulted in significantly altered treatment plans for more than half of the cases in which a patient's primary diagnosis had been provided from referring hospitals in China.
GlaxoSmithKline and Genmab A/S announced today an amendment to the ofatumumab co-development and commercialisation agreement. Under the terms of the amendment, GSK will take responsibility for developing ofatumumab in autoimmune indications whilst continuing to jointly develop ofatumumab with Genmab in oncology indications.
Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).
Prof. Jiunn-Der Liao of Department of Materials Science and Engineering at National Cheng Kung University (NCKU), Tainan, Taiwan, has led Post Doctorate Chih-Chiang Weng and a research team to develop a pen-size plasma sterilization device which can sterilize instruments and wounds by relying on the process of plasma sterilization.
› Verified 6 days ago